{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T21:19:05Z","timestamp":1788988745627,"version":"build-2803163510"},"reference-count":50,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2024,11,2]],"date-time":"2024-11-02T00:00:00Z","timestamp":1730505600000},"content-version":"vor","delay-in-days":306,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,1,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>PRAME (Preferentially expressed Antigen in Melanoma) is a cancer\u2013testis antigen expressed in several tumor indications, representing an attractive anticancer target. However, its intracellular location limits targeting by traditional methods. PRAME peptides are presented on the surface of tumor cells by human leukocyte antigen (HLA) molecules, indicating that a T cell receptor (TCR)-based strategy that redirects T cells to kill PRAME+ tumors could be a novel immunotherapeutic option. We confirm that PRAME protein is expressed in cutaneous melanoma, including rare subtypes with limited treatment options, as well as primary and metastatic lung, breast, endometrial, and ovarian tumors. Furthermore, PRAME is expressed homogeneously across tumors with distinct oncogenic mutations, mutation burden, PD-L1 expression, immune infiltration, and features of immune checkpoint resistance. Immunopeptidomic analysis of primary tumors detected HLA class I-restricted PRAME peptides.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>A TCR recognizing PRAME peptide SLLQHLIGL was engineered to high affinity and fused to a CD3 engaging domain to create a TCRxCD3 bispecific molecule (Immune-mobilizing monoclonal TCR Against Cancer, ImmTAC\u00ae) with the ability to redirect polyclonal T cells to efficiently kill PRAME+ cells.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Rs<\/jats:title>\n                  <jats:p>The degree of T cell activation was positively correlated with peptide\u2013HLA abundance, with as few as 10 epitopes per cell sufficient for target cell killing. Impaired ImmTAC\u00ae-redirected cytotoxicity of exhausted T cells was rescued using an anti-PD-1 antibody, supporting the use of a combination strategy to treat tumors with active PDL1-PD1 axes.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Our data demonstrate selective and efficient T cell activation and killing by a PRAME-directed TCRxCD3 bispecific, supporting further investigation in multiple cancer indications.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/immadv\/ltae008","type":"journal-article","created":{"date-parts":[[2024,11,2]],"date-time":"2024-11-02T11:13:50Z","timestamp":1730546030000},"source":"Crossref","is-referenced-by-count":7,"title":["High-affinity T cell receptor ImmTAC\u00ae bispecific efficiently redirects T cells to kill tumor cells expressing the cancer\u2013testis antigen PRAME"],"prefix":"10.1093","volume":"4","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-3983-7219","authenticated-orcid":false,"given":"Ana R","family":"Ribeiro","sequence":"first","affiliation":[{"name":"Immunocore Limited , Abingdon, Oxfordshire ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camille","family":"Britton-Rivet","sequence":"additional","affiliation":[{"name":"Immunocore Limited , Abingdon, Oxfordshire ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Collins","sequence":"additional","affiliation":[{"name":"Immunocore Limited , Abingdon, Oxfordshire ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricardo J","family":"Carreira","sequence":"additional","affiliation":[{"name":"Immunocore Limited , Abingdon, Oxfordshire ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvie","family":"Moureau","sequence":"additional","affiliation":[{"name":"Immunocore Limited , Abingdon, Oxfordshire ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adel","family":"Benlahrech","sequence":"additional","affiliation":[{"name":"Immunocore Limited , Abingdon, Oxfordshire ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Stanhope","sequence":"additional","affiliation":[{"name":"Immunocore Limited , Abingdon, Oxfordshire ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6029-8668","authenticated-orcid":false,"given":"Stephen","family":"Harper","sequence":"additional","affiliation":[{"name":"Immunocore Limited , Abingdon, Oxfordshire ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathaniel","family":"Liddy","sequence":"additional","affiliation":[{"name":"Immunocore Limited , Abingdon, Oxfordshire ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tara M","family":"Mahon","sequence":"additional","affiliation":[{"name":"Immunocore Limited , Abingdon, Oxfordshire ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristina","family":"Petrovic","sequence":"additional","affiliation":[{"name":"Immunocore Limited , Abingdon, Oxfordshire ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Fife","sequence":"additional","affiliation":[{"name":"Immunocore Limited , Abingdon, Oxfordshire ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Depoil","sequence":"additional","affiliation":[{"name":"Immunocore Limited , Abingdon, Oxfordshire ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Addis","sequence":"additional","affiliation":[{"name":"Immunocore Limited , Abingdon, Oxfordshire ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Bedke","sequence":"additional","affiliation":[{"name":"Immunocore Limited , Abingdon, Oxfordshire ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucie","family":"Bouard","sequence":"additional","affiliation":[{"name":"Immunocore Limited , Abingdon, Oxfordshire ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronan","family":"O\u2019Dwyer","sequence":"additional","affiliation":[{"name":"Immunocore Limited , Abingdon, Oxfordshire ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Duncan","family":"Gascoyne","sequence":"additional","affiliation":[{"name":"Immunocore Limited , Abingdon, Oxfordshire ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koustubh","family":"Ranade","sequence":"additional","affiliation":[{"name":"Immunocore Limited , Abingdon, Oxfordshire ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,11,2]]},"reference":[{"key":"2024121100370807100_CIT0001","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.1097\/PAS.0000000000001134","article-title":"PRAME expression in melanocytic tumors","volume":"42","author":"Lezcano","year":"2018","journal-title":"Am J Surg Pathol"},{"key":"2024121100370807100_CIT0002","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/s1074-7613(00)80426-4","article-title":"Characterization of an antigen that is recognized on a melanoma showing partial HLA loss by CTL expressing an NK inhibitory receptor","volume":"6","author":"Ikeda","year":"1997","journal-title":"Immunity"},{"key":"2024121100370807100_CIT0003","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1016\/j.cell.2005.07.003","article-title":"The human tumor antigen PRAME is a dominant repressor of retinoic acid receptor signaling","volume":"122","author":"Epping","year":"2005","journal-title":"Cell"},{"key":"2024121100370807100_CIT0004","first-page":"185","article-title":"PRAME is a potential carcinogenic biomarker that correlates with patient prognosis and tumor immunity based on pan-cancer analysis","volume":"52","author":"Zhao","year":"2022","journal-title":"Ann Clin Lab Sci"},{"key":"2024121100370807100_CIT0005","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1097\/PAS.0000000000001944","article-title":"PRAME expression in cancer. A systematic immunohistochemical study of &gt;5800 epithelial and nonepithelial tumors","volume":"46","author":"Kaczorowski","year":"2022","journal-title":"Am J Surg Pathol"},{"key":"2024121100370807100_CIT0006","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1038\/sj.bjc.6604494","article-title":"PRAME expression and clinical outcome of breast cancer","volume":"99","author":"Epping","year":"2008","journal-title":"Br J Cancer"},{"key":"2024121100370807100_CIT0007","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1159\/000381533","article-title":"PRAME expression and its clinical relevance in Hodgkin\u2019s lymphoma","volume":"134","author":"Ercolak","year":"2015","journal-title":"Acta Haematol"},{"key":"2024121100370807100_CIT0008","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1158\/1078-0432.CCR-15-2071","article-title":"PRAME as an independent biomarker for metastasis in uveal melanoma","volume":"22","author":"Field","year":"2016","journal-title":"Clin Cancer Res"},{"key":"2024121100370807100_CIT0009","doi-asserted-by":"publisher","first-page":"4307","DOI":"10.1158\/1078-0432.CCR-03-0813","article-title":"The tumor-associated antigen PRAME is universally expressed in high-stage neuroblastoma and associated with poor outcome","volume":"10","author":"Oberthuer","year":"2004","journal-title":"Clin Cancer Res"},{"key":"2024121100370807100_CIT0010","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1159\/000487353","article-title":"Downregulation of PRAME suppresses proliferation and promotes apoptosis in hepatocellular carcinoma through the activation of P53 mediated pathway","volume":"45","author":"Zhu","year":"2018","journal-title":"Cell Physiol Biochem"},{"key":"2024121100370807100_CIT0011","doi-asserted-by":"publisher","first-page":"984","DOI":"10.3390\/cancers11070984","article-title":"Cancer testis antigens and immunotherapy: where do we stand in the targeting of PRAME","volume":"11","author":"Al-Khadairi","year":"2019","journal-title":"Cancers"},{"key":"2024121100370807100_CIT0012","doi-asserted-by":"crossref","first-page":"5615","DOI":"10.1158\/1078-0432.CCR-11-1066","article-title":"PRAME-specific Allo-HLA\u2013restricted T cells with potent antitumor reactivity useful for therapeutic T-cell receptor gene transfer","volume":"17","author":"Amir","year":"2011","journal-title":"Clin Cancer Res"},{"key":"2024121100370807100_CIT0013","first-page":"1376","article-title":"PRAME, a","volume":"102","author":"Baren","year":"1998","journal-title":"Brit J Haematol"},{"key":"2024121100370807100_CIT0014","doi-asserted-by":"publisher","first-page":"e12770","DOI":"10.1111\/cpr.12770","article-title":"The role of the cancer testis antigen PRAME in tumorigenesis and immunotherapy in human cancer","volume":"53","author":"Xu","year":"2020","journal-title":"Cell Prolif"},{"key":"2024121100370807100_CIT0015","doi-asserted-by":"publisher","first-page":"3353","DOI":"10.1182\/blood-2010-08-300376","article-title":"High-avidity cytotoxic T lymphocytes specific for a new PRAME-derived peptide can target leukemic and leukemic-precursor cells","volume":"117","author":"Quintarelli","year":"2011","journal-title":"Blood"},{"key":"2024121100370807100_CIT0016","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1182\/blood-2008-04-150045","article-title":"Cytotoxic T lymphocytes directed to the preferentially expressed antigen of melanoma (PRAME) target chronic myeloid leukemia","volume":"112","author":"Quintarelli","year":"2008","journal-title":"Blood"},{"key":"2024121100370807100_CIT0017","doi-asserted-by":"crossref","first-page":"2208","DOI":"10.1016\/j.jtho.2016.08.120","article-title":"Safety and immunogenicity of the PRAME cancer immunotherapeutic in patients with resected non\u2013small cell lung cancer: a phase I dose escalation study","volume":"11","author":"Pujol","year":"2016","journal-title":"J Thorac Oncol"},{"key":"2024121100370807100_CIT0018","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1097\/CJI.0b013e3182280db1","article-title":"A phase 1 study of a vaccine targeting preferentially expressed antigen in melanoma and prostate-specific membrane antigen in patients with advanced solid tumors","volume":"34","author":"Weber","year":"2011","journal-title":"J Immunother"},{"key":"2024121100370807100_CIT0019","doi-asserted-by":"publisher","first-page":"e000068","DOI":"10.1136\/esmoopen-2016-000068","article-title":"Safety and immunogenicity of the PRAME cancer immunotherapeutic in metastatic melanoma: results of a phase I dose escalation study","volume":"1","author":"Gutzmer","year":"2016","journal-title":"Esmo Open"},{"key":"2024121100370807100_CIT0020","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1093\/protein\/gzg087","article-title":"Stable, soluble T-cell receptor molecules for crystallization and therapeutics","volume":"16","author":"Boulter","year":"2003","journal-title":"Protein Eng Des Sel"},{"key":"2024121100370807100_CIT0021","doi-asserted-by":"publisher","first-page":"5869","DOI":"10.1158\/1078-0432.CCR-20-1247","article-title":"Tebentafusp, A TCR\/Anti-CD3 bispecific fusion protein targeting gp100, potently activated antitumor immune responses in patients with metastatic melanoma","volume":"26","author":"Middleton","year":"2020","journal-title":"Clin Cancer Res"},{"key":"2024121100370807100_CIT0022","doi-asserted-by":"publisher","first-page":"971","DOI":"10.3390\/cancers11070971","article-title":"Tebentafusp: T cell redirection for the treatment of metastatic uveal melanoma","volume":"11","author":"Damato","year":"2019","journal-title":"Cancers"},{"key":"2024121100370807100_CIT0023","doi-asserted-by":"publisher","first-page":"2364","DOI":"10.1038\/s41591-022-02015-7","article-title":"Clinical and molecular response to tebentafusp in previously treated patients with metastatic uveal melanoma: a phase 2 trial","volume":"28","author":"Carvajal","year":"2022","journal-title":"Nat Med"},{"key":"2024121100370807100_CIT0024","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1056\/NEJMoa2103485","article-title":"Overall survival benefit with Tebentafusp in metastatic uveal melanoma","volume":"385","author":"Nathan","year":"2021","journal-title":"N Engl J Med"},{"key":"2024121100370807100_CIT0025","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/nature14664","article-title":"Comprehensive genomic profiles of small cell lung cancer","volume":"524","author":"George","year":"2015","journal-title":"Nature"},{"key":"2024121100370807100_CIT0026","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1016\/j.cell.2018.09.006","article-title":"A cancer cell program promotes T cell exclusion and resistance to checkpoint blockade","volume":"175","author":"Jerby-Arnon","year":"2018","journal-title":"Cell"},{"key":"2024121100370807100_CIT0027","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1038\/nm.2764","article-title":"Monoclonal TCR-redirected tumor cell killing","volume":"18","author":"Liddy","year":"2012","journal-title":"Nat Med"},{"key":"2024121100370807100_CIT0028","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1038\/nbt1070","article-title":"Directed evolution of human T-cell receptors with picomolar affinities by phage display","volume":"23","author":"Li","year":"2005","journal-title":"Nat Biotechnol"},{"key":"2024121100370807100_CIT0029","doi-asserted-by":"publisher","first-page":"109429","DOI":"10.1016\/j.celrep.2021.109429","article-title":"A pan-cancer organoid platform for precision medicine","volume":"36","author":"Larsen","year":"2021","journal-title":"Cell Rep"},{"key":"2024121100370807100_CIT0030","doi-asserted-by":"publisher","first-page":"e26840","DOI":"10.4161\/onci.26840","article-title":"Examining the presentation of tumor-associated antigens on peptide-pulsed T2 cells","volume":"2","author":"Bossi","year":"2013","journal-title":"Oncoimmunology"},{"key":"2024121100370807100_CIT0031","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.isci.2018.03.009","article-title":"YY1 upregulates checkpoint receptors and downregulates type I cytokines in exhausted, chronically stimulated human T cells","volume":"2","author":"Balkhi","year":"2018","journal-title":"iScience"},{"key":"2024121100370807100_CIT0032","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1186\/s13059-016-1070-5","article-title":"Estimating the population abundance of tissue-infiltrating immune and stromal cell populations using gene expression","volume":"17","author":"Becht","year":"2016","journal-title":"Genome Biol"},{"key":"2024121100370807100_CIT0033","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1093\/bioinformatics\/btp616","article-title":"edgeR: a Bioconductor package for differential expression analysis of digital gene expression data","volume":"26","author":"Robinson","year":"2010","journal-title":"Bioinformatics"},{"key":"2024121100370807100_CIT0034","doi-asserted-by":"publisher","first-page":"2847","DOI":"10.1093\/bioinformatics\/btw313","article-title":"Complex heatmaps reveal patterns and correlations in multidimensional genomic data","volume":"32","author":"Gu","year":"2016","journal-title":"Bioinformatics"},{"key":"2024121100370807100_CIT0035","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1177\/10668969211012085","article-title":"Immunohistochemical detection of cancer-testis antigen PRAME","volume":"29","author":"Lezcano","year":"2021","journal-title":"Int J Surg Pathol"},{"key":"2024121100370807100_CIT0036","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1093\/oncolo\/oyac091","article-title":"Management of Acral and mucosal melanoma: medical oncology perspective","volume":"27","author":"Jung","year":"2022","journal-title":"Oncologist"},{"key":"2024121100370807100_CIT0037","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1186\/s40425-019-0647-4","article-title":"Tumor mutational burden quantification from targeted gene panels: major advancements and challenges","volume":"7","author":"Fancello","year":"2019","journal-title":"J ImmunoTher Cancer"},{"key":"2024121100370807100_CIT0038","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1038\/nature21349","article-title":"Elements of cancer immunity and the cancer\u2013immune set point","volume":"541","author":"Chen","year":"2017","journal-title":"Nature"},{"key":"2024121100370807100_CIT0039","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1016\/S0140-6736(21)01206-X","article-title":"Immune checkpoint inhibitors in melanoma","volume":"398","author":"Carlino","year":"2021","journal-title":"Lancet"},{"key":"2024121100370807100_CIT0040","doi-asserted-by":"publisher","first-page":"153","DOI":"10.7888\/juoeh.41.153","article-title":"Treatment of non-small cell lung cancer with EGFR-mutations","volume":"41","author":"Yoneda","year":"2019","journal-title":"J UOEH"},{"key":"2024121100370807100_CIT0041","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1159\/000443368","article-title":"Drug resistance to EGFR inhibitors in lung cancer","volume":"61","author":"Tetsu","year":"2016","journal-title":"Chemotherapy"},{"key":"2024121100370807100_CIT0042","doi-asserted-by":"crossref","first-page":"2500","DOI":"10.1056\/NEJMc1713444","article-title":"Tumor mutational burden and response rate to PD-1 inhibition","volume":"377","author":"Mark","year":"2017","journal-title":"New Engl J Med"},{"key":"2024121100370807100_CIT0043","doi-asserted-by":"publisher","first-page":"e212","DOI":"10.1111\/ajco.12586","article-title":"Gene expression of MAGE-A3 and PRAME tumor antigens and EGFR mutational status in Taiwanese non\u2013small cell lung cancer patients","volume":"13","author":"Pan","year":"2017","journal-title":"Asia Pac J Clin Oncol"},{"key":"2024121100370807100_CIT0044","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1385\/IR:21:2-3:315","article-title":"The thymus and negative selection","volume":"21","author":"Kishimoto","year":"2000","journal-title":"Immunol Res"},{"key":"2024121100370807100_CIT0045","doi-asserted-by":"publisher","first-page":"3130","DOI":"10.1158\/1078-0432.CCR-05-2578","article-title":"Detection and functional analysis of CD8+ T cells specific for PRAME: a target for T-cell therapy","volume":"12","author":"Griffioen","year":"2006","journal-title":"Clin Cancer Res"},{"key":"2024121100370807100_CIT0046","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1084\/jem.193.1.73","article-title":"Efficient identification of novel Hla-A*0201\u2013presented cytotoxic T lymphocyte epitopes in the widely expressed tumor antigen prame by proteasome-mediated digestion analysis","volume":"193","author":"Kessler","year":"2001","journal-title":"J Exp Med"},{"key":"2024121100370807100_CIT0047","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1016\/j.leukres.2011.04.005","article-title":"Inhibition of PRAME expression causes cell cycle arrest and apoptosis in leukemic cells","volume":"35","author":"Tanaka","year":"2011","journal-title":"Leuk Res"},{"key":"2024121100370807100_CIT0048","doi-asserted-by":"publisher","first-page":"e2016857118","DOI":"10.1073\/pnas.2016857118","article-title":"DNA origami demonstrate the unique stimulatory power of single pMHCs as T cell antigens","volume":"118","author":"Hellmeier","year":"2021","journal-title":"Proc Natl Acad Sci USA"},{"key":"2024121100370807100_CIT0049","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1038\/ni1058","article-title":"T cell killing does not require the formation of a stable mature immunological synapse","volume":"5","author":"Purbhoo","year":"2004","journal-title":"Nat Immunol"},{"key":"2024121100370807100_CIT0050","doi-asserted-by":"publisher","first-page":"17588359231160140","DOI":"10.1177\/17588359231160140","article-title":"Tebentafusp: a first-in-class treatment for metastatic uveal melanoma","volume":"15","author":"Howlett","year":"2023","journal-title":"Ther Adv Med Oncol"}],"container-title":["Immunotherapy Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/immunotherapyadv\/advance-article-pdf\/doi\/10.1093\/immadv\/ltae008\/60328745\/ltae008.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/immunotherapyadv\/article-pdf\/4\/1\/ltae008\/61008707\/ltae008.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/immunotherapyadv\/article-pdf\/4\/1\/ltae008\/61008707\/ltae008.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,11]],"date-time":"2024-12-11T01:13:36Z","timestamp":1733879616000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/immunotherapyadv\/article\/doi\/10.1093\/immadv\/ltae008\/7866557"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,1]]},"references-count":50,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1,1]]}},"URL":"https:\/\/doi.org\/10.1093\/immadv\/ltae008","relation":{},"ISSN":["2732-4303"],"issn-type":[{"value":"2732-4303","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024]]},"published":{"date-parts":[[2024,1,1]]},"article-number":"ltae008"}}